Vadim Koshkin, MD

Dr. Vadim Koshkin is a genitourinary medical oncologist at the University of California San Francisco where he leads the bladder cancer clinical program in medical oncology. He completed his medical degree at the University of Chicago Pritzker School of Medicine, internal medicine training at the University of Michigan and fellowship in medical oncology at the Cleveland Clinic, and his interests are focused in clinical and translational research of bladder and prostate cancer.

Articles by Vadim Koshkin, MD

Vadim Koshkin, MDAdvanced Urothelial Carcinoma | April 15, 2025
Drs. Koshkin and Nizam discuss how a longer treatment-free interval may predict benefit from pembrolizumab rechallenge.
View More
Vadim Koshkin, MDAdvanced Urothelial Carcinoma | April 15, 2025
Drs. Koshkin and Nizam break down recent research on pembro in patients with la/mUC who responded to first-course pembro.
Vadim Koshkin, MDUrothelial Carcinoma Diagnostics | April 7, 2025
Dr. Koshkin highlights emerging data on Nectin-4–targeted imaging and radiopharmaceuticals in urothelial cancer.
Vadim Koshkin, MDUrothelial Carcinoma Diagnostics | April 7, 2025
Dr. Koshkin shares an overview of FAP-targeted theranostics, including UCSF-led studies showing FAP PET imaging’s ability.
Tanya Dorff, MDmHSPC | February 27, 2025
The panel highlights the limitations of conventional imaging in detecting disease progression at undetectable PSA levels.
Tanya Dorff, MDmHSPC | February 26, 2025
The panel zooms in on the use of radium, enzalutamide, and other therapeutic agents, touching on patient preference trials.
Tanya Dorff, MDmHSPC | February 26, 2025
The panel focuses on decision-making between AR antagonists and abiraterone, weighing factors such as reimbursement.
Tanya Dorff, MDmHSPC | February 26, 2025
The panel goes in-depth on the use of testing and SBRT as metastasis-directed therapy in newly diagnosed prostate cancer.
Tanya Dorff, MDmHSPC | February 26, 2025
The panel explores the the role of imaging, genomics, and patient factors in the management of mHSPC.
Karine Tawagi, MDMuscle Invasive Urothelial Carcinoma | October 19, 2024
In the final part of this roundtable, Drs. Koshkin and Grivas discuss the use of EV/pembro and which patients are eligible.
Karine Tawagi, MDMuscle Invasive Urothelial Carcinoma | October 18, 2024
In part five of this roundtable, the panelists explore the use of ctDNA in the TOMBOLA and IMvigor011 trials.
Karine Tawagi, MDMuscle Invasive Urothelial Carcinoma | October 18, 2024
In the fourth part of this roundtable series, the panelists discuss recent updates on bladder-sparing treatments.
Karine Tawagi, MDMuscle Invasive Urothelial Carcinoma | October 15, 2024
In part 3 of this roundtable, the NIAGARA trial is discussed, along with cisplatin regimens and the potential of durvalumab.
Karine Tawagi, MDMuscle Invasive Urothelial Carcinoma | October 15, 2024
In the second part of this roundtable, new trials including VOLGA and EV-304 are analyzed.
Karine Tawagi, MDMuscle Invasive Urothelial Carcinoma | October 15, 2024
In part 1, the panelists examine the evolving treatment landscape of MIBC and NMIBC, including discussion on new trials.
Vadim Koshkin, MDAdvanced Urothelial Carcinoma | September 23, 2024
Dr. Koshkin highlights phase 2 data on futibatinib plus pembrolizumab for advanced urothelial carcinoma.
Christos Kyriakopoulos, MDCRPC | June 4, 2024
Drs. Kyriakopoulos and Koshkin break down the CHAARTED2 trial of the ECOG-ACRIN Cancer Research Group.
Vadim Koshkin, MDAdvanced Urothelial Carcinoma | May 28, 2024
Drs. Koshkin and Nizam discuss the trastuzumab deruxtecan FDA approval and the DESTINY-PanTumor02 clinical trial.
Vadim Koshkin, MDUrothelial Carcinoma | February 12, 2024
The outcomes related to sacituzumab govitecan for patients with variant histologies are highlighted.
Vadim Koshkin, MDAdvanced Urothelial Carcinoma | May 20, 2024
The potential for sequencing erdafitinib and EV for patients with FGFR2/3-altered disease is considered.